Toward the development of a hepatitis E vaccine

Virus Research

Volumn 161, Issue 1, 2011, Pages 93-100

  Kamili, Saleem ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

DNA vaccine; Hepatitis E; HEV; Macaques; Vaccine

Indexed keywords

BACULOVIRUS VECTOR; HEPATITIS E VACCINE; HEV 239; UNCLASSIFIED DRUG;

ACUTE HEPATITIS; DRUG EFFICACY; ENDEMIC DISEASE; ESCHERICHIA COLI; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; INTESTINE INFECTION; MACACA; MORBIDITY; MORTALITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; VIRUS CAPSID;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

ESCHERICHIA COLI; HEPATITIS E VIRUS; MACACA; MIRIDAE;

EID: 80053178957     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.05.008     Document Type: Review

References (65)

1. Aggarwal, R. Clinical presentation of hepatitis E. Virus Res., this issue.
2. Ahmad, I., Holla, R.P., Jameel, S. Molecular virology of hepatitis E virus. Virus Res., this issue.
3. Arankalle V.A., Chadha M.S., Chobe L.P. Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus. J. Hepatol. 1999, 30(2):199-204.
4. Arankalle V.A., Chadha M.S., Chobe L.P., Nair R., Banerjee K. Cross-challenge studies in rhesus monkeys employing different Indian isolates of hepatitis E virus. J. Med. Virol. 1995, 46(4):358-363.
5. Arankalle V.A., Favorov M.O., Chadha M.S., Phule D.M., Banerjee K. Rhesus monkeys infected with hepatitis E virus (HEV) from the former USSR are immune to subsequent challenge with an Indian strain of HEV. Acta Virol. 1993, 37(6):515-518.
6. Arankalle V.A., Lole K.S., Deshmukh T.M., Srivastava S., Shaligram U.S. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccinees: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes. Vaccine 2009, 27(7):1032-1039.
7. Bi S.L., Purdy M.A., McCaustland K.A., Margolis H.S., Bradley D.W. The sequence of hepatitis E virus isolated directly from a single source during an outbreak in China. Virus Res. 1994, 33(1):98.
8. Bryan J.P., Tsarev S.A., Iqbal M., Ticehurst J., Emerson S., Ahmed A., Duncan J., Rafiqui A.R., Malik I.A., Purcell R.H. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J. Infect. Dis. 1994, 170(3):517-521.
9. Deshmukh T.M., Lole K.S., Tripathy A.S., Arankalle V.A. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice. Vaccine 2007, 25(22):4350-4360.
10. Emerson S.U., Anderson D., Arankalle V.A., Meng X.J., Purdy M.A., Schlauder G.G., Tsarev S.A. Virus Taxonomy. VIIIth Report of the ICTV 2004, Elsevier/Academic Press, London, pp. 851-855.
11. Guthmann J.P., Klovstad H., Boccia D., Hamid N., Pinoges L., Nizou J.Y., Tatay M., Diaz F., Moren A., Grais R.F., Ciglenecki I., Nicand E., Guerin P.J. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin. Infect. Dis. 2006, 42(12):1685-1691.
12. Hamid S.S., Atiq M., Shehzad F., Yasmeen A., Nissa T., Salam A., Siddiqui A., Jafri W. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002, 36(2):474-478.
13. He J., Hoffman S.L., Hayes C.G. DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice. Vaccine 1997, 15(4):357-362.
14. Holmberg S.D. Hepatitis E vaccine: not a moment too soon. Lancet 2010, 376(9744):849-851.
15. Im S.W., Zhang J.Z., Zhuang H., Che X.Y., Zhu W.F., Xu G.M., Li K., Xia N.S., Ng M.H. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus. Vaccine 2001, 19(27):3726-3732.
16. Kamar N., Garrouste C., Haagsma E.B., Garrigue V., Pischke S., Chauvet C., Dumortier J., Cannesson A., Cassuto-Viguier E., Thervet E., Conti F., Lebray P., Dalton H.R., Santella R., Kanaan N., Essig M., Mousson C., Radenne S., Roque-Afonso A.M., Izopet J., Rostaing L. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011.
17. Kamar N., Selves J., Mansuy J.M., Ouezzani L., Peron J.M., Guitard J., Cointault O., Esposito L., Abravanel F., Danjoux M., Durand D., Vinel J.P., Izopet J., Rostaing L. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med. 2008, 358(8):811-817.
18. Kamili S., Spelbring J., Carson D., Krawczynski K. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. J. Infect. Dis. 2004, 189(2):258-264.
19. Kamili S., Spelbring J., Krawczynski K. DNA vaccination against hepatitis E virus infection in cynomolgus macaques. J. Gastroenterol. Hepatol. 2002, 17(Suppl 3):S365-S369.
20. Khuroo, M.S. Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res., this issue.
21. Khuroo M.S. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am. J. Med. 1980, 68(6):818-824.
22. Khuroo M.S., Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J. Viral Hepat. 2003, 10(1):61-69.
23. Khuroo M.S., Kamili S., Dar M.Y., Moecklii R., Jameel S. Hepatitis E and long-term antibody status. Lancet 1993, 341(8856):1355.
24. Khuroo M.S., Teli M.R., Skidmore S., Sofi M.A., Khuroo M.I. Incidence and severity of viral hepatitis in pregnancy. Am. J. Med. 1981, 70:252-255.
25. Krawczynski K. Hepatitis E vaccine-ready for prime time?. N. Engl. J. Med. 2007, 356(9):949-951.
26. Krawczynski, K., Meng, X.J., Rybczynska, J. Pathogenetic elements of hepatitis E and animal models of HEV infection. Virus Res., this issue.
27. Kui X., Sun M., Xie T., Wang W., Jiang L., Yan M., Ma K., Li H. The expression, purification, and immunogenicity of a new chimeric virus-like particle. Viral Immunol. 2009, 22(1):49-56.
28. Li F., Torresi J., Locarnini S.A., Zhuang H., Zhu W., Guo X., Anderson D.A. Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked. J. Med. Virol. 1997, 52(3):289-300.
29. Li S.W., Zhang J., He Z.Q., Gu Y., Liu R.S., Lin J., Chen Y.X., Ng M.H., Xia N.S. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J. Biol. Chem. 2005, 280(5):3400-3406.
30. Li S.W., Zhang J., Li Y.M., Ou S.H., Huang G.Y., He Z.Q., Ge S.X., Xian Y.L., Pang S.Q., Ng M.H., Xia N.S. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005, 23(22):2893-2901.
31. Li T., Takeda N., Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001, 19(25-26):3476-3484.
32. Li T.C., Suzaki Y., Ami Y., Dhole T.N., Miyamura T., Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004, 22(3-4):370-377.
33. Li T.C., Takeda N., Miyamura T., Matsuura Y., Wang J.C., Engvall H., Hammar L., Xing L., Cheng R.H. Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J. Virol. 2005, 79(20):12999-13006.
34. Li T.C., Yamakawa Y., Suzuki K., Tatsumi M., Razak M.A., Uchida T., Takeda N., Miyamura T. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 1997, 71(10):7207-7213.
35. Liu M.A. DNA vaccinees: an historical perspective and view to the future. Immunol. Rev. 2011, 239(1):62-84.
36. McAtee C.P., Zhang Y., Yarbough P.O., Fuerst T.R., Stone K.L., Samander S., Williams K.R. Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry. J. Chromatogr. B Biomed. Appl. 1996, 685(1):91-104.
37. Miyamura and Hepatitis E, Miyamura, T. Hepatitis E virus infection in developed countries. Virus Res., this issue.
38. Niikura M., Takamura S., Kim G., Kawai S., Saijo M., Morikawa S., Kurane I., Li T.C., Takeda N., Yasutomi Y. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002, 293(2):273-280.
39. Okamoto, H. Hepatitis E virus cell culture models. Virus Res., this issue.
40. Purcell R.H., Emerson S.U. Animal models of hepatitis A and E. ILAR J. 2001, 42(2):161-177.
41. Purcell R.H., Nguyen H., Shapiro M., Engle R.E., Govindarajan S., Blackwelder W.C., Wong D.C., Prieels J.P., Emerson S.U. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 2003, 21(19-20):2607-2615.
42. Purdy M.A., McCaustland K.A., Krawczynski K., Spelbring J., Reyes G.R., Bradley D.W. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J. Med. Virol. 1993, 41(1):90-94.
43. Purdy M.A., McCaustland K.A., Krawczynski K., Tam A., Beach M.J., Tassopoulos N.C., Reyes G.R., Bradley D.W. Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recognized by antibodies in sera from human cases and experimentally infected primates. Arch. Virol. 1992, 123(3-4):335-349.
44. Renoux V.M., Fleury M.J., Bousarghin L., Gaitan J., Sizaret P.Y., Touze A., Coursaget P. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine 2008, 26(51):6602-6607.
45. Robinson R.A., Burgess W.H., Emerson S.U., Leibowitz R.S., Sosnovtseva S.A., Tsarev S., Purcell R.H. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expr. Purif. 1998, 12(1):75-84.
46. Safary A. Perspectives of vaccination against hepatitis E. Intervirology 2001, 44(2-3):162-166.
47. Shrestha M.P., Scott R.M., Joshi D.M., Mammen M.P., Thapa G.B., Thapa N., Myint K.S., Fourneau M., Kuschner R.A., Shrestha S.K., David M.P., Seriwatana J., Vaughn D.W., Safary A., Endy T.P., Innis B.L. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 2007, 356(9):895-903.
48. Takamura S., Niikura M., Li T.C., Takeda N., Kusagawa S., Takebe Y., Miyamura T., Yasutomi Y. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. 2004, 11(7):628-635.
49. Tam A.W., White R., Yarbough P.O., Murphy B.J., McAtee C.P., Lanford R.E., Fuerst T.R. In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes. Virology 1997, 238(1):94-102.
50. Teo C.G. The two clinico-epidemiological forms of hepatitis E. J. Viral Hepat. 2007, 14(5):295-297.
51. Teshale E.H., Howard C.M., Grytdal S.P., Handzel T.R., Barry V., Kamili S., Drobeniuc J., Okware S., Downing R., Tappero J.W., Bakamutumaho B., Teo C.G., Ward J.W., Holmberg S.D., Hu D.J. Hepatitis E epidemic. Uganda. Emerg. Infect. Dis. 2010, 16(1):126-129.
52. Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L., Purcell R.H. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(21):10198-10202.
53. Tsarev S.A., Tsareva T.S., Emerson S.U., Govindarajan S., Shapiro M., Gerin J.L., Purcell R.H. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997, 15(17-18):1834-1838.
54. Tuteja R., Li T.C., Takeda N., Jameel S. Augmentation of immune responses to hepatitis E virus ORF2 DNA vaccination by codelivery of cytokine genes. Viral Immunol. 2000, 13(2):169-178.
55. Vishwanathan R. Infectious hepatitis in Delhi (1955-1956): a critical study: epidemiology. Indian J. Med. Res. 1957, 45(Suppl. 1):1-29.
56. Wu T., Wu X.L., Ou S.H., Lin C.X., Cheng T., Li S.W., Ng M.H., Zhang J., Xia N.S. Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Mol. Immunol. 2007, 44(12):3261-3266.
57. Xing L., Kato K., Li T., Takeda N., Miyamura T., Hammar L., Cheng R.H. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T=1 particle presenting native virus epitopes. Virology 1999, 265(1):35-45.
58. Yang S., Wang C., Fang X., Zhai L., Dong C., Ding L., Meng J., Wang L. Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization. Virus Res. 2010, 151(2):162-169.
59. Yarbough P.O. Hepatitis E virus. Advances in HEV biology and HEV vaccine approaches. Intervirology 1999, 42(2-3):179-184.
60. Zhang J., Gu Y., Ge S.X., Li S.W., He Z.Q., Huang G.Y., Zhuang H., Ng M.H., Xia N.S. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 2005, 23(22):2881-2892.
61. Zhang J., Liu C.B., Li R.C., Li Y.M., Zheng Y.J., Li Y.P., Luo D., Pan B.B., Nong Y., Ge S.X., Xiong J.H., Shih J.W., Ng M.H., Xia N.S. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009, 27(12):1869-1874.
62. Zhang J.Z., Ng M.H., Xia N.S., Lau S.H., Che X.Y., Chau T.N., Lai S.T., Im S.W. Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein. J. Med. Virol. 2001, 64(2):125-132.
63. Zhang M., Emerson S.U., Nguyen H., Engle R., Govindarajan S., Blackwelder W.C., Gerin J., Purcell R.H. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. Vaccine 2002, 20(27-28):3285-3291.
64. Zhang M., Emerson S.U., Nguyen H., Engle R.E., Govindarajan S., Gerin J.L., Purcell R.H. Immunogenicity and protective efficacy of a vaccine prepared from 53kDa truncated hepatitis E virus capsid protein expressed in insect cells. Vaccine 2001, 20(5-6):853-857.
65. Zhu F.C., Zhang J., Zhang X.F., Zhou C., Wang Z.Z., Huang S.J., Wang H., Yang C.L., Jiang H.M., Cai J.P., Wang Y.J., Ai X., Hu Y.M., Tang Q., Yao X., Yan Q., Xian Y.L., Wu T., Li Y.M., Miao J., Ng M.H., Shih J.W., Xia N.S. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010, 376(9744):895-902.